Reported Tuesday, Sep 29 - 4:02pm EDT (TheFly subscription required to read more.)

Maravai LifeSciences anticipates meeting its 2024 revenue targets, with preliminary results tracking toward the middle of previously announced guidance range.

ROSEN, A TOP RANKED LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI

The Insomniac Hedge Fund

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes for molecular biology, have executed a licensing agreement for a proprietary Optimer® binder developed for...

Reported Wednesday, Sep 9 - 7:28am EDT (TheFly subscription required to read more.)

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Analyst Recommendations This is a breakdown of current [...]

Wells Fargo & Stifel say Moderna-Merck Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher & Maravai LifeSciences.

Avantor (NYSE:AVTR – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Volatility & Risk Avantor has a beta of 0.89, [...]

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) released its earnings results on Thursday. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02, FiscalAI reports. Maravai LifeSciences had a negative return on equity of 15.34% and a negative net margin of 37.07%.The company had revenue of $51.44 [...]

Maravai posted $8.7M in adjusted EBITDA as TriLink revenue increased 11.5%; 2026 revenue guidance remains $205M-$215M.

Reported Thursday, Aug 6 - 4:04pm EDT (TheFly subscription required to read more.)

Reported Thursday, Aug 6 - 4:05pm EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

Maravai LifeSciences (NASDAQ: MRVI), through its subsidiary TriLink BioTechnologies, has received a new patent from the China National Intellectual Property Administration (CNIPA), patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules with its CleanCap® capping analogs, including the latest M6 analog.The allowed claims cover co-transcriptional RNA synthesis using trimer or tetramer capping structures, strengthening TriLink’s intellectual property in China. CleanCap® technology is also patented in major markets including the US, EU, Australia, Japan, Korea, Hong Kong, and Canada, and has been used in approved COVID-19 mRNA and saRNA vaccines and broader RNA therapeutic programs.

Die Maravai-LifeSciences-Aktie steht nach den jüngsten Quartalszahlen und einem vorsichtigen Ausblick im Fokus von Anlegern. Umsatzrückgang im Kerngeschäft, anhaltende Profitabilität und ein unsicherer Ausblick auf Covid-bezogene Erlöse prägen das Bild.